Drug Combination Details
| General Information of the Combination (ID: C98479) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | C1632 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lip/oral cavity/pharynx neoplasm
[ICD-11: 2B6E]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | HMGA2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | Lin-28A | Molecule Info | |||
| In-vitro Model | SCC-9 | CVCL_1685 | Tongue squamous cell carcinoma | Homo sapiens | ||
| CAL-27 | CVCL_1107 | Tongue squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | Each nude mouse was subcutaneously injected in the flank back skin with 200 uL of serum-free DMEM containing 8 * 106 CAL27 cells. | |||||
| Experimental
Result(s) |
C1632 and metformin exerts synergistic anti-tumor effects in OSCC cell lines SCC9 and CAL27, and also inhibits xenograft tumor growth in vivo. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma. Eur J Pharmacol. 2021 Jan 15;891:173757. | |||
